Candidate: Camostat mesylate

Type: Inhibitor of the serine protease TMPRSS2. The drug is approved in Japan and South Korea for use in pancreatic inflammation.

Status: University of Aarhus on March 25 disclosed via plans for the Phase I/II CamoCO-19 trial (NCT04321096). The estimated 180-patient, placebo-controlled randomized clinical trial is designed to assess camostat mesilate as a potential treatment for COVID-19. The study’s estimated primary completion date is December 31, 2020.

The trial was launched less than a month after a research team led by investigators at the German Primate Center reported in the journal Cell that they tested SARS-CoV-2 isolated from a patient, and found that camostat mesilate blocked entry of the virus into lung cells. “Our results suggest that camostat mesilate might also protect against COVID-19,” stated lead author Markus Hoffmann, PhD, of the Primate Center.

COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:


Previous articleSinopharm Group (Wuhan Institute of Biological Products) and Chinese Academy of Sciences (Wuhan Institute of Virology)
Next articleCynata Therapeutics